Contact: [email protected]
| Title | Tumor type | Line | Study information |
|---|---|---|---|
| MS202359_002 (XRay Vision) | SCCHN | Adjuvant | Resected high risk LA SSCHN, cisplatinum ineligible; RT + xevinapant/placebo |
| Hyperlynx | SCCHN | 1L | Unresected LA SSCHN stage III, IVA, IVB; Xevinapant + cisplatin + RT |